🎯 Drug Targets

Browse 5 drug targets with druggability analysis, composite scores, and clinical context

5

Targets

0

High Druggability

0.54

Avg Score

15

Target Classes

Druggability Distribution

High: 0Medium: 0Low: 5Unknown: 0

Avg druggability score: 0.392

Clinical Pipeline

Approved: 1Phase III: 0Phase II: 2Phase I: 2Preclinical: 0

Total compounds: 15 · Approved: 1

Filtered by: class=kinase, druggability=Low — 5 results

ULK1 Unc-51 like autophagy activating kinase 1 Phase I

Kinase Low Druggability

Small molecule activators or inhibitors of ULK1 kinase activity to modulate autophagy

EPHB4 Ephrin type-B receptor 4 Approved

Kinase Low Druggability

Small molecule inhibitor of receptor tyrosine kinase activity

SRPK1 SRSF protein kinase 1 Phase II

Kinase Low Druggability

SRPK1 inhibitors block phosphorylation of serine/arginine-rich splicing factors, modulating alternative splicing patterns implicated in neurodegeneration and cancer. By preventing aberrant splicing, these inhibitors can restore normal protein isoform expression and reduce pathogenic tau accumulation.

MLCK Myosin light chain kinase Phase II

Kinase Low Druggability

MLCK inhibitors block the phosphorylation of myosin light chains, thereby reducing cytoskeletal contraction and stabilizing tight junctions at the blood-brain barrier and endothelial surfaces. This mechanism reduces vascular permeability and preserves barrier integrity in conditions characterized by excessive leakage or cytoskeletal dysfunction.

MTOR Mechanistic Target of Rapamycin Phase I

Kinase Low Druggability

Prioritized from 1 SciDEX hypotheses, including: APOE-Dependent Autophagy Restoration